Flozins, or SGLT2 inhibitors, are a game changer. They are the drugs that nephrologists have been waiting for. Added to the basic blockade of the renin-angiotensin-aldosterone system, they extend patients' lives by more than a third. Nephrologists haven't had this kind of therapeutic range for a long time. What's more, these are drugs that work at different stages of chronic kidney damage, both in the early and late stages. The less often patients enter post renal failure, the less often they need to take renal replacement therapy. Be the period to reach hemodialysis or peritoneal dialysis or kidney transplantation is simply longer. For these patients, it is donated time.
Since phlozins attached to primary RAA blockade reduce albuminuria and even inhibit it, given at early stages of the disease, they can lead to reversal of changes that have not yet become established in the kidneys. Conversely, by reducing albuminuria in later stages, they influence and fundamentally modify cardiovascular risk in these patients. Because patients with kidney disease don't die from uremia, they die from heart attacks and strokes, that is, from cardiovascular complications. And, unfortunately, they die many times more often than the population without chronic kidney disease.
This is a ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
